Vi e w p o i n t | 07 Aug 2026 02:30:15 ET │ 12 pages Biomarin Pharmaceutical Inc (BMRN.O) 2Q Takeaways: Accelerated Synergy, Deleveraging Outlook on Amicus Integration CITI'S TAKE Building from a solid 2Q performance, delivering both top- and bottom-line beats (product revenue +6%, non-GAAP EPS +30% vs VA cons), core messaging from BioMarin's call was an upgraded accretive outlook on the Amicus acquisition, with raised peak sales forecasts for Galafold and Pom+Op ($1.4B and $1.2B, respectively, by the mid- ...